Incidence of acute radiodermatitis in women with breast cancer undergoing hypofractionated radiotherapy

Abstract

Objective: To estimate the incidence and degree of acute radiodermatitis at the end and after the end of treatment in women with breast cancer undergoing hypofractionated radiotherapy. Methods: Observational, prospective, and longitudinal study, conducted between March 2019 and January 2020, in a radiotherapy outpatient clinic. Results: Thirty-two women participated in the study, among whom, in the last session of hypofractionated radiotherapy, 15 (46.9%) had radiodermatitis, erythema in 13 (40.6%), and wet peeling in 2 (6.3%). In the post-treatment evaluation, 27 (84.4%) had radiodermatitis, erythema in 17 (53.1%), dry peeling in 8 (25%), and wet peeling in 2 (6.3%). Conclusion: The general incidence of radiodermatitis after hypofractionated radiotherapy in women with breast cancer was 37.5%, erythema, 12.5%, and dry peeling, 25%. The development of care protocols for the management of radiodermatitis after treatment is of paramount importance.

Factors on development and severity of acute radiodermatitis: prospective single-center study

“…There was a relationship between total dose and RD by the literature. RT dose and fraction scheme play an important role in the development of RD (21). Consistent with the literature, a significant relationship was found between the total dose and RD in our study.…”

Photobiomodulation therapy for the prevention of acute radiation dermatitis: a systematic review and meta-analysis

“…In breast cancer (BC) patients, roughly 90% and 30% of patients have historically developed grade 1 and 2 reactions, respectively [ 5 ]. Recent advances in RT techniques have significantly lowered the severity of RD, with the incidence after hypo-fractionated breast RT being approximately 38% [ 6 ]. In head and neck cancer (HNC) patients, mild reactions develop in virtually all subjects, but more severe and dose-limiting toxicities happen in almost a fifth of irradiated subjects [ 7 ].…”

A Chitosan-Coated Chamomile Microparticles Formulation to Prevent Radiodermatitis in Breast

“…[1][2][3][4] The development of RD is multifactorial, depending on patients and treatment-related factors. [5][6][7][8][9][10][11] Although RT has passed through a significant technological advance in the last decade, the RD still is a common adverse effect observed in clinical practice.…”

“…Radiodermatitis (RD) is the most frequent collateral effect from adjuvant RT, and all patients undergoing RT are at risk of developing RD 1–4. The development of RD is multifactorial, depending on patients and treatment-related factors 5–11. Although RT has passed through a significant technological advance in the last decade, the RD still is a common adverse effect observed in clinical practice.…”